{"entity":{"id":"nct06125080","kind":"trial","name":"The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospec","aka":["UTILIZABLE"],"tldr":"A phase 2 trial of utidelone and bevacizumab in triple-negative breast cancer, run by Huihua Xiong, now recruiting.","summary":"The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study is a phase 2, interventional study registered as NCT06125080 by Huihua Xiong, with a registry enrolment figure of 78 participants, started 2023-10-30 and due to reach its primary completion in 2025-10-30. Interventions recorded: Utidelone; Tirelizumab; Bevacizumab. Conditions listed: TNBC - Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: \"Patients voluntarily participated in the study, signed the informed consent, and had good compliance; Female patients aged 18-70; TNBC confirmed by histology or cytology\". Sites: China. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT06125080","url":"https://clinicaltrials.gov/study/NCT06125080"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-metastatic"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":["utidelone","bevacizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06125080","phase":"2","setting":"The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ：Single-arm, Prospective, Open Clinical Study","sponsor":"Huihua Xiong","participation":[{"nct":"NCT06125080","source":"https://clinicaltrials.gov/study/NCT06125080","fetchedAt":"2026-10-07T16:54:14.819Z","studySha256":"2bfae1db9affa27509105d6d26d609ef0d46c358a8aa97d0642c4ea9bc3623d2","overallStatus":"RECRUITING","lastUpdatePosted":"2023-11-09","leadSponsor":"Huihua Xiong","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"70 Years","sex":"FEMALE","healthyVolunteers":false,"hasEligibility":true,"enrolment":78,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2023-10-30","startedType":"estimated","enrolled":78,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06125080/","neighbours":{"cancer":[{"id":"tnbc-metastatic","kind":"cancer","name":"Metastatic triple-negative breast cancer","route":"/cancers/tnbc-metastatic/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"drug":[{"id":"bevacizumab","kind":"drug","name":"Bevacizumab","route":"/drugs/bevacizumab/"},{"id":"utidelone","kind":"drug","name":"Utidelone","route":"/drugs/utidelone/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}